The microbiome therapeutics developer, which was spun out of Wellcome Sanger Institute, completed a $66.6m round co-led by Tencent

Internet group Tencent co-led a £50m ($66.6m) series B round for UK-headquartered microbiome-based therapeutics developer Microbiotica yesterday with life sciences investment firm Flerie.

British Patient Capital, Cambridge Innovation Capital, IP Group and Seventure Partners also participated in the round, together with Cambridge Innovation Capital, the investment fund backed by University of Cambridge.

Spun out of genomics research institute Wellcome Sanger Institute in 2016, Microbiotica is developing drugs based on research isolating gut bacteria, in order to fight diseases including cancer…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn